fda ruling on compounded semaglutide glp 1 altRx GLP-1 Review 2026: Updated for the Latest FDA Compounded The FDA has received reports

First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study

Lyxumia (lixisenatide) Summary of Product Characteristics

Zealand Pharmas Licensing Agreement With Roche To Disrupt GLP-1 Obesity Treatment Market Pharmaceuticals / Denmark / Thu 13 Mar, 2025 Zealand Pharma's agreement with Roche to jointly develop and commercialise an experimental amylin-based weight-loss treatment will create a strong obesity treatment franchise

Use of Glucagon-Like Peptide-1 Agonists and Increased Risk of Procedural Sedation and Endotracheal Intubation in the Emergency Department

Roussou E et al